Neuren Pharmaceuticals (ASX:NEU) has announced that the US FDA has reviewed Neuren’s Investigational New Drug application for NNZ-2591 in Prader-Willi syndrome. …
FDA approves IND for Prader-Willi syndrome study of Neuren's NNZ-2591
January 26, 2023 Australian Biotech
Latest Video
New Stories
-
The Week in Review Podcast - 19 April
April 19, 2024 - - Podcast -
New Novartis-backed report identifies nuclear medicine opportunity but calls for change
April 19, 2024 - - Latest News -
Scope of practice review recommends formation of new committee
April 19, 2024 - - Latest News -
The HTA review reference committee members should ask themselves one question
April 18, 2024 - - Latest News -
If coercion and retribution are bad for supermarket customers, they must be bad for patients
April 18, 2024 - - Latest News -
AbbVie announces the appointment of new Australia-NZ human resources director
April 18, 2024 - - BioPharma -
'Under Karen’s leadership our local business has thrived both commercially and culturally'
April 18, 2024 - - Latest News